Perceptive Advisors LLC
About Perceptive Advisors LLC’s 13F portfolio
Perceptive Advisors LLC is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Perceptive Advisors LLC reported $6.4B across 102 US-listed positions (). Its largest position is PRAXIS PRECISION MEDICINES I (PRAX) at 11% of the reported book, and its ten biggest holdings make up 49% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.
| # | Stock | Price | % of portfolio | Shares | Value |
|---|---|---|---|---|---|
| 1 | NASDAQ: PRAX PRAXIS PRECISION MEDICINES I | $305.19 +0.04% | 11% | 2.0M | $681.6M |
| 2 | NASDAQ: SYRE SPYRE THERAPEUTICS INC | $101.46 +8.15% | 6.0% | 4.3M | $383.5M |
| 3 | NASDAQ: CELC CELCUITY INC | $55.60 −4.15% | 5.2% | 3.2M | $334.5M |
| 4 | NASDAQ: ASND ASCENDIS PHARMA A/S | $270.33 −0.32% | 4.8% | 1.2M | $310.4M |
| 5 | NASDAQ: RYTM RHYTHM PHARMACEUTICALS INC | $119.04 +2.08% | 4.5% | 2.6M | $287.2M |
| 6 | NASDAQ: ROIV ROIVANT SCIENCES LTD | $38.73 +0.05% | 4.4% | 8.1M | $286.1M |
| 7 | NASDAQ: RLAY RELAY THERAPEUTICS INC | $16.51 +0.24% | 4.1% | 14.1M | $263.9M |
| 8 | NASDAQ: TVTX TRAVERE THERAPEUTICS INC | $50.24 −1.68% | 3.3% | 3.8M | $213.2M |
| 9 | NASDAQ: KARD KARDIGAN INC | — — | 3.0% | 8.2M | $195.6M |
| 10 | NASDAQ: NUVL NUVALENT INC | $123.96 0.00% | 3.0% | 1.6M | $195.2M |
| 11 | NASDAQ: EWTX EDGEWISE THERAPEUTICS INC | $41.37 −1.59% | 2.8% | 4.4M | $177.7M |
| 12 | NASDAQ: APGE APOGEE THERAPEUTICS INC | $135.07 0.00% | 2.7% | 1.3M | $173.6M |
| 13 | NASDAQ: AMLX AMYLYX PHARMACEUTICALS INC | $26.62 −3.27% | 2.3% | 8.3M | $149.7M |
| 14 | NASDAQ: MGTX MEIRAGTX HLDGS PLC | $8.32 −1.65% | 2.3% | 10.8M | $145.7M |
| 15 | NASDAQ: ORKA ORUKA THERAPEUTICS INC | $95.74 −0.60% | 2.0% | 1.3M | $128.0M |
| 16 | NASDAQ: INBX INHIBRX BIOSCIENCES INC | $69.06 −6.90% | 1.9% | 1.3M | $123.0M |
| 17 | NASDAQ: PTGX PROTAGONIST THERAPEUTICS INC | $127.16 +2.00% | 1.9% | 982K | $120.4M |
| 18 | NASDAQ: SLDB SOLID BIOSCIENCES INC | $6.35 +1.93% | 1.8% | 11.9M | $118.9M |
| 19 | NASDAQ: ZYME ZYMEWORKS INC | $26.04 +0.77% | 1.7% | 4.2M | $109.3M |
| 20 | NASDAQ: TNGX TANGO THERAPEUTICS INC | $21.89 −1.00% | 1.6% | 3.4M | $105.6M |
| 21 | NASDAQ: IMTX IMMATICS N.V | $6.10 −3.02% | 1.6% | 10.4M | $105.2M |
| 22 | NASDAQ: NRIX NURIX THERAPEUTICS INC | $14.10 −0.98% | 1.6% | 4.3M | $104.8M |
| 23 | NASDAQ: BCRX BIOCRYST PHARMACEUTICALS INC | $7.30 −2.67% | 1.6% | 10.3M | $103.1M |
| 24 | NASDAQ: RVMD REVOLUTION MEDICINES INC | $159.82 −1.76% | 1.5% | 528K | $98.8M |
| 25 | NASDAQ: AVLN AVALYN PHARMACEUTICALS INC | — — | 1.4% | 2.7M | $88.1M |
Showing 1–25 of 102 positions on this page reported in this 13F.
- Healthcare94%
- AddedSYRESPYRE THERAPEUTICS INC+14.2%$383.5M
- AddedCELCCELCUITY INC+2.2%$334.5M
- NewASNDASCENDIS PHARMA A/S—$310.4M
- AddedRYTMRHYTHM PHARMACEUTICALS INC+9.0%$287.2M
- AddedRLAYRELAY THERAPEUTICS INC+44.7%$263.9M
- NewKARDKARDIGAN INC—$195.6M
- AddedAMLXAMYLYX PHARMACEUTICALS INC+0.6%$149.7M
- AddedMGTXMEIRAGTX HLDGS PLC+4.5%$145.7M
- AddedZYMEZYMEWORKS INC+19.2%$109.3M
- AddedTNGXTANGO THERAPEUTICS INC+318%$105.6M
- ReducedROIVROIVANT SCIENCES LTD−2.4%$286.1M
- ReducedTVTXTRAVERE THERAPEUTICS INC−9.4%$213.2M
- ReducedEWTXEDGEWISE THERAPEUTICS INC−1.1%$177.7M
- ReducedAPGEAPOGEE THERAPEUTICS INC−15.1%$173.6M
- ReducedORKAORUKA THERAPEUTICS INC−3.6%$128.0M
- ReducedINBXINHIBRX BIOSCIENCES INC−10.0%$123.0M
- ReducedPTGXPROTAGONIST THERAPEUTICS INC−20.2%$120.4M
- ReducedDYNDYNE THERAPEUTICS INC−42.4%$59.7M
- ReducedIMVTIMMUNOVANT INC−15.0%$52.3M
- ReducedANROALTO NEUROSCIENCE INC−19.9%$42.5M
Companies where this manager has disclosed a stake of more than 5% of a class of shares, as reported to the SEC on Schedule 13D (activist) or 13G (passive). Figures are as disclosed in each filing — tap a date to open the source document.
| # | Stock | Type | % of class | Shares | Filed |
|---|---|---|---|---|---|
| 1 | ADGM Adagio Medical Holdings, Inc. | 13G | 57.5% · 3 classes | 15.3M | Filed 17 FEB 2026 |
| 2 | LONA LeonaBio, Inc. | 13D | 20.0% · 2 classes | 1.9M | Filed 26 OCT 2026 |
| 3 | SLDB Solid Biosciences Inc. | 13D | 12.9% · 2 classes | 12.0M | Filed 11 MAR 2026 |
| 4 | MGTX MeiraGTx Holdings plc | 13D | 12.9% · 2 classes | 10.4M | Filed 02 JAN 2026 |
| 5 | FRNM Freenome, Inc. | 13G | 11.3% | 12.6M | Filed 16 NOV 2026 |
| 6 | NAUT Nautilus Biotechnology, Inc. | 13D | 10.1% | 12.8M | Filed 24 JUN 2025 |
| 7 | TRIB Trinity Biotech plc | 13D | 10.0% · 3 classes | 54.1M | Filed 10 NOV 2026 |
| 8 | PALI PALISADE BIO, INC. | 13G | 10.0% · 2 classes | 15.2M | Filed 17 FEB 2026 |
| 9 | IKT INHIBIKASE THERAPEUTICS, INC. | 13G | 10.0% · 2 classes | 12.8M | Filed 17 FEB 2026 |
| 10 | IRD Opus Genetics, Inc. | 13G | 10.0% · 2 classes | 7.2M | Filed 17 FEB 2026 |
| 11 | ENGN enGene Holdings Inc. | 13G | 10.0% · 3 classes | 6.9M | Filed 14 AUG 2026 |
| 12 | OBIO Orchestra BioMed Holdings, Inc. | 13G | 10.0% · 2 classes | 5.7M | Filed 14 NOV 2025 |
| 13 | ANRO Alto Neuroscience, Inc. | 13G | 10.0% · 2 classes | 4.2M | Filed 14 AUG 2026 |
| 14 | NVNO enVVeno Medical Corporation | 13G | 10.0% | 2.0M | Filed 17 FEB 2026 |
| 15 | VYNE Yarrow Bioscience, Inc. | 13G | 10.0% | 1.6M | Filed 16 NOV 2026 |
| 16 | INBX INHIBRX BIOSCIENCES, INC. | 13G | 10.0% | 1.5M | Filed 14 AUG 2026 |
| 17 | KPHMW KIORA PHARMACEUTICALS, INC. | 13G | 10.0% | 442K | Filed 10 AUG 2026 |
| 18 | RLAY KIORA PHARMACEUTICALS, INC. | 13G | 10.0% · 2 classes | 438K | Filed 13 APR 2026 |
| 19 | TENX Tenax Therapeutics, Inc. | 13G | 9.1% | 569K | Filed 17 FEB 2026 |
| 20 | RACD Research Alliance Corporation IV | 13G | 9.0% | 700K | Filed 16 NOV 2026 |
| 21 | KARD Kardigan, Inc. | 13D | 8.8% | 8.3M | Filed 01 OCT 2026 |
| 22 | QNCX IRulya Therapeutics Inc. | 13G | 8.4% | 913K | Filed 14 OCT 2026 |
| 23 | AMLX Amylyx Pharmaceuticals, Inc. | 13G | 8.2% · 2 classes | 9.0M | Filed 14 NOV 2025 |
| 24 | XFOR X4 PHARMACEUTICALS, INC. | 13G | 8.1% · 2 classes | 8.1M | Filed 14 AUG 2026 |
| 25 | IVVD INVIVYD, INC. | 13G | 7.9% | 21.8M | Filed 25 NOV 2025 |
Showing 1–25 of 39 disclosed stakes. 5 last disclosed over a year ago (the holder may since have dropped below 5%).
Reading Perceptive Advisors LLC’s 13F portfolio
Perceptive Advisors LLC’s $6.4B 13F book is spread across 102 reported positions and is concentrated toward its biggest ideas, with the top ten holdings at 49%. The largest positions carry real weight, so how those names perform matters a lot to the overall book. Its five largest positions are PRAX, SYRE, CELC, ASND and RYTM, led by PRAXIS PRECISION MEDICINES I (PRAX) at 11% of the portfolio. The heaviest sector exposure is Healthcare (94%).
What Perceptive Advisors LLC changed last quarter
Between 2026-03-31 and Q2 2026, Perceptive Advisors LLC was a net buyer: it opened 23 new positions and added to 30 more, while trimming 26 and closing 13 outright. Against a 102-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was SPYRE THERAPEUTICS INC (SYRE), and its biggest reduction was ROIVANT SCIENCES LTD (ROIV).
What a 13F does and doesn’t reveal
A 13F captures only Perceptive Advisors LLC’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Perceptive Advisors LLC is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.
Frequently asked questions
What is an SEC 13F filing?
A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Perceptive Advisors LLC's profile on this page is built directly from those filings.
How current is the 13F data on Perceptive Advisors LLC's page?
It reflects Perceptive Advisors LLC's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Perceptive Advisors LLC files its next quarterly report, this page refreshes automatically.
Can I see Perceptive Advisors LLC's complete list of holdings?
This page highlights Perceptive Advisors LLC's largest positions rather than all 102 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Perceptive Advisors LLC's filings.
Does a 13F show everything Perceptive Advisors LLC owns?
No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Perceptive Advisors LLC's book rather than its full strategy or total assets.
Is 13F data investment advice?
No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Perceptive Advisors LLC made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.
Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.

